142 results on '"Adotevi, O."'
Search Results
2. LBA6 UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer
3. 180P Recalling pre-existing microbiota-specific T cells to target tumors
4. 203P Early remodeling of systemic antitumor T cell immunity in head and neck cancer patients treated by chemoradiation
5. 210P Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell on circulating antitumor CD4+ Th1 response in patients treated by anti-PD(L)-1
6. P02.07 Innate immunity atlas of hepatocellular carcinoma unravels the differentiation hierarchy of myeloid NK cells and MDSCs
7. P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer
8. Valeur pronostique de la lymphopénie T CD4 + dans le cancer du poumon non à petites cellules
9. Immunité spécifique anti-télomérase dans le mélanome
10. Les auteurs
11. Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients
12. Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
13. P1.14-19 Exome Analysis of Patients Treated with Afatinib Reveals Genetic Variations Discriminating Extreme Responders
14. Increased Levels of Interleukin-17A Exosomes in Psoriasis
15. Interest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy
16. Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)
17. Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy
18. The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer
19. Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors
20. Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols
21. Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors
22. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial
23. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
24. Presence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma
25. Generation and characterization of cord blood derived T cells redirected with a TCR targeting E7/HLA-DR4 complex
26. Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer
27. 1903P - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
28. 1789P - Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients
29. Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer
30. Étude des mécanismes impliqués dans la modulation des réponses immunitaires T antitumorales induites par la radio-chimiothérapie concomitante (RTCTc)
31. Étude des mécanismes d’activation des réponses T CD4 antitumorale induites par la chimioradiothérapie : résultats préliminaires
32. 30TiP - Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)
33. 92P - Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy
34. 40P - Interest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy
35. 1356P - The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer
36. 415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors
37. Étude de l’influence de la mutation BRAF sur l’expression tumorale de l’ARNm hTERT et sur l’infiltrat lymphocytaire intra-tumoral dans le mélanome
38. Étude de la corrélation de l’immunité CD4 Th1 anti-télomérase dans le mélanome avec l’expression tumorale de la télomérase et l’infiltrat lymphocytaire intra-tumoral
39. 1656P - Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer
40. B subunit of shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity
41. Prognostic Value of Angiopoietin-2 for Overall Survival in Patients with Metastatic Colorectal Carcinoma Treated By Chemotherapy and Bevacizumab
42. 1081P - The efficacy of everolimus relies on a modulation of adaptative anti tumor T cell immunity
43. Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy.
44. T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
45. Immunogenic HLA-B7-restricted peptides of hTRT
46. Modulation de la réponse immunitaire anti-tumorale induite par docétaxel, cisplatine et 5-fluorouracile (DCF) dans un modèle de cancer du canal anal
47. 211P - Prognostic Value of Angiopoietin-2 for Overall Survival in Patients with Metastatic Colorectal Carcinoma Treated By Chemotherapy and Bevacizumab
48. 660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study.
49. c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells
50. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.